Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not a subscriber? Subscribe now for unlimited access to online articles.

  • China Photos | Getty
  • Rewriting Life

    CRISPR may not cause hundreds of rogue mutations after all

    Researchers behind a controversial paper have admitted that their results may be wrong.

    A scientific journal has retracted a controversial paper, published last year, that suggested the gene-editing tool CRISPR was a genome wrecking ball.

    In the retracted study, researchers sought to use CRISPR in mice to correct a mutation that causes blindness. They successfully fixed the genetic error but reported that CRISPR inadvertently made more than a thousand other changes—potentially harmful ones—in the animals’ DNA.

    It didn’t take long for the results, published in Nature Methods, to spark panic that CRISPR might be too dangerous to use in humans. The findings hadn’t been observed by other researchers and immediately drew criticism from people including executives at the big three gene-editing companies, CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics—whose stocks tumbled after the study was published.

    Today, Nature Methods retracted the paper, saying in an accompanying editorial that “there was insufficient data to support the claim of unexpected off-target effects due to CRISPR.”

    As the first clinical trials using CRISPR are ramping up in Europe and the US, that’s welcome news to companies and patients standing to benefit from the technology. In statements provided to MIT Technology Review, Editas and Intellia said they were pleased that the scientific process was able to “correct the record.”

    CRISPR is a biological system that can be programmed to precisely cut segments of DNA. It’s been touted as a permanent cure for genetic diseases and as a more effective cancer treatment. But questions still remain about how safe it is and how well it could actually work in the body.

    So-called off-target effects—accidental cuts to DNA in other than the intended parts of the genome—have been a major concern about moving CRISPR from animal experiments to people. Cutting the wrong section of DNA could give rise to cancer or other health problems. But the number of these changes reported in the retracted study seemed suspiciously high.

    Earlier this week, the authors of the original paper posted an article on the pre-print server bioRxiv saying that they couldn’t replicate their previous results.  

    Of course, the retraction doesn’t mean CRISPR is completely problem-free.

    “On the question of whether CRISPR can be safely used [in the body], the stakes are high for many. But for none are they higher than for the people in whom this technology may be used in the future. They are owed a careful and rigorous answer,” the Nature Methods editorial says.

    But other researchers are breathing a sigh of relief over the news, if not celebrating outright. “My reaction to hearing of the retraction: it’s about time,” says Samuel Sternberg, a biochemist and CRISPR expert at Columbia University.

    Keep up with the latest in biotechnology at EmTech MIT.
    Discover where tech, business, and culture converge.

    September 17-19, 2019
    MIT Media Lab

    Register now
    More from Rewriting Life

    Reprogramming our bodies to make us healthier.

    Want more award-winning journalism? Subscribe to MIT Technology Review.
    • Print + All Access Digital {! insider.prices.print_digital !}* Best Value

      {! insider.display.menuOptionsLabel !}

      The best of MIT Technology Review in print and online, plus unlimited access to our online archive, an ad-free web experience, discounts to MIT Technology Review events, and The Download delivered to your email in-box each weekday.

      See details+

      12-month subscription

      Unlimited access to all our daily online news and feature stories

      6 bi-monthly issues of print + digital magazine

      10% discount to MIT Technology Review events

      Access to entire PDF magazine archive dating back to 1899

      Ad-free website experience

      The Download: newsletter delivery each weekday to your inbox

      The MIT Technology Review App

    • All Access Digital {! insider.prices.digital !}*

      {! insider.display.menuOptionsLabel !}

      The digital magazine, plus unlimited site access, our online archive, and The Download delivered to your email in-box each weekday.

      See details+

      12-month subscription

      Unlimited access to all our daily online news and feature stories

      Digital magazine (6 bi-monthly issues)

      Access to entire PDF magazine archive dating back to 1899

      The Download: newsletter delivery each weekday to your inbox

    • Print Subscription {! insider.prices.print_only !}*

      {! insider.display.menuOptionsLabel !}

      Six print issues per year plus The Download delivered to your email in-box each weekday.

      See details+

      12-month subscription

      Print magazine (6 bi-monthly issues)

      The Download: newsletter delivery each weekday to your inbox

    /3
    You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.